Cochrane Abstracts
Long‐acting muscarinic antagonist (LAMA) plus long‐acting beta‐agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Long‐acting Muscarinic Antagonist (LAMA) Plus Long‐acting Beta‐agonist (LABA) Versus LABA Plus Inhaled Corticosteroid (ICS) for Stable Chronic Obstructive Pulmonary Disease." Cochrane Abstracts, John Wiley & Sons, Inc, 2025. Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/431206/all/Long‐acting_muscarinic_antagonist__LAMA__plus_long‐acting_beta‐agonist__LABA__versus_LABA_plus_inhaled_corticosteroid__ICS__for_stable_chronic_obstructive_pulmonary_disease.
Long‐acting muscarinic antagonist (LAMA) plus long‐acting beta‐agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease. Cochrane Abstracts. John Wiley & Sons, Inc; 2025. https://evidence.unboundmedicine.com/evidence/view/Cochrane/431206/all/Long‐acting_muscarinic_antagonist__LAMA__plus_long‐acting_beta‐agonist__LABA__versus_LABA_plus_inhaled_corticosteroid__ICS__for_stable_chronic_obstructive_pulmonary_disease. Accessed January 14, 2025.
Long‐acting muscarinic antagonist (LAMA) plus long‐acting beta‐agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease. (2025). In Cochrane Abstracts. John Wiley & Sons, Inc. https://evidence.unboundmedicine.com/evidence/view/Cochrane/431206/all/Long‐acting_muscarinic_antagonist__LAMA__plus_long‐acting_beta‐agonist__LABA__versus_LABA_plus_inhaled_corticosteroid__ICS__for_stable_chronic_obstructive_pulmonary_disease
Long‐acting Muscarinic Antagonist (LAMA) Plus Long‐acting Beta‐agonist (LABA) Versus LABA Plus Inhaled Corticosteroid (ICS) for Stable Chronic Obstructive Pulmonary Disease [Internet]. In: Cochrane Abstracts. John Wiley & Sons, Inc; 2025. [cited 2025 January 14]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/431206/all/Long‐acting_muscarinic_antagonist__LAMA__plus_long‐acting_beta‐agonist__LABA__versus_LABA_plus_inhaled_corticosteroid__ICS__for_stable_chronic_obstructive_pulmonary_disease.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Long‐acting muscarinic antagonist (LAMA) plus long‐acting beta‐agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease
ID - 431206
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/431206/all/Long‐acting_muscarinic_antagonist__LAMA__plus_long‐acting_beta‐agonist__LABA__versus_LABA_plus_inhaled_corticosteroid__ICS__for_stable_chronic_obstructive_pulmonary_disease
PB - John Wiley & Sons, Inc
DB - Evidence Central
DP - Unbound Medicine
ER -
